Fusion Antibodies (LON:FAB) Shares Down 1.2% – Should You Sell?

Fusion Antibodies plc (LON:FAB)’s share price dropped 1.2% during mid-day trading on Wednesday . The stock traded as low as GBX 10.60 and last traded at GBX 10.62. Approximately 107,224 shares were traded during mid-day trading, a decline of 75% from the average session volume of 431,250 shares. The stock had previously closed at GBX 10.75.

Fusion Antibodies Trading Up 7.3%

The business’s 50 day moving average price is GBX 12.34 and its 200-day moving average price is GBX 13.20. The company has a market cap of £13.77 million, a price-to-earnings ratio of -7.33 and a beta of 1.22. The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.